Lysosomal Targeting Chimeras Targeting Protein Degradation
Undisclosed RD pain
Lycia Therapeutics is developing tools to degrade extracellular proteins exploiting knowledge of lysosomes. Lysosomes are cellular organelles that are hubs for protein degradation. Using their Lysosomal Targeting Chimera (LYTAC) platform, Lycia is hijacking the endogenous lysosomal trafficking shuttle to target the untapped extracellular proteome. The LYTAC platform can be extended to both board-based and tissue-specific targeting enabling several therapeutic modalities. Lycia is advancing an undisclosed discovery pipeline of novel LYTAC degraders for clearing protein aggregates and immune complexes, removal of circulating antibodies and degrading challenging membrane targets to treat autoimmune and inflammatory diseases.
Scientist I/II Molecular Biology & Protein Express...
San Francisco, CA|32 days ago
Principal/Senior Scientist, Pharmacokinetics/Model...
San Francisco, CA|71 days ago